Twist Bioscience (NASDAQ:TWST) Price Target Raised to $55.00

Twist Bioscience (NASDAQ:TWST) had its price target lifted by Guggenheim from $50.00 to $55.00 in a report published on Monday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities analysts also recently commented on TWST. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, February 3rd. Barclays increased their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Finally, Evercore raised their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

Twist Bioscience Stock Up 4.3%

Twist Bioscience stock opened at $49.54 on Monday. The firm has a market capitalization of $3.04 billion, a P/E ratio of -38.70 and a beta of 2.20. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $57.88. The stock’s fifty day simple moving average is $46.74 and its 200-day simple moving average is $37.03.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. The company’s revenue was up 16.9% compared to the same quarter last year. As a group, equities analysts expect that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CAO Robert F. Werner sold 7,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $45.65, for a total value of $319,550.00. Following the completion of the transaction, the chief accounting officer owned 58,738 shares in the company, valued at approximately $2,681,389.70. This represents a 10.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Dennis Cho sold 5,000 shares of the stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00. Following the completion of the transaction, the insider directly owned 138,581 shares in the company, valued at $6,919,349.33. This trade represents a 3.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,190 shares of company stock valued at $2,234,695 over the last three months. 3.08% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. Stifel Financial Corp boosted its stake in Twist Bioscience by 3.6% in the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after acquiring an additional 271 shares in the last quarter. D.A. Davidson & CO. increased its position in shares of Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares in the last quarter. CWM LLC lifted its holdings in shares of Twist Bioscience by 9.4% in the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after purchasing an additional 407 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after purchasing an additional 442 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.